Massachusetts is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of DF6002 Alone and in Combination With Nivolumab
NCT04423029
Recruiting
The purpose of this study is to evaluate the safety, tolerability, drug-levels, drug-effects and preliminary anti-tumor activity of DF6002 alone and in combination with Nivolumab in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution, Boston, Massachusetts
Conditions: Solid Tumors
Register for Updates
Intervention For AYAS With Cancer Risk Syndromes
NCT04323774
Recruiting
This research is being done because there is a need to improve cancer risk communication and decision-making among adolescents and young adults. In this study, the investigators are looking at whether using a chatbot and online portal for cancer risk information helps improve communication and decision-making. * Over 70,000 adolescents and young adults (AYAs) are diagnosed with cancer in the U.S. every year and up to 10% have genetic changes (or, mutations) that put them at a higher risk of dev... Read More
Gender:
ALL
Ages:
Between 12 years and 24 years
Trial Updated:
01/28/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Cancer Risk Syndrome
Register for Updates
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
NCT03317158
Recruiting
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Urothelial Carcinoma, Bladder Cancer
Register for Updates
Open Pilot Trial of a Mind-body Program for Cardiac Arrest Survivors and Their Caregivers
NCT06517394
Recruiting
The purpose of this study is to pilot a mind-body intervention for cardiac arrest survivors and their informal caregivers, Recovering Together after Cardiac Arrest. The data the investigators gather in this study will be used to further refine our intervention.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Emotional Distress, Cardiac Arrest
Register for Updates
Cryoablation for Monomorphic Ventricular Tachycardia
NCT05675865
Recruiting
The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio VT Cryoablation System in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Sustained VT
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Avo In R/R And Previously Untreated MCL
NCT04855695
Recruiting
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Mantle Cell Lymphoma, Refractory Lymphoma
Register for Updates
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
NCT04555161
Recruiting
This prospective study is a multi-center early feasibility study assessing the safety and performance of the Aria CV Pulmonary Hypertension System in patients with pulmonary hypertension and right heart dysfunction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
Register for Updates
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
NCT04134559
Recruiting
This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).
Gender:
ALL
Ages:
Between 0 years and 30 years
Trial Updated:
01/27/2025
Locations: Children's Hospital Boston, Boston, Massachusetts
Conditions: Hepatocellular Carcinoma, Childhood, Liver Cancer, Fibrolamellar Carcinoma, Liver Cancer, Pediatric
Register for Updates
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835
Recruiting
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: Massachusetts General Hospital - Dana Farber, Boston, Massachusetts
Conditions: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
Register for Updates
Fecal Microbiota Transplant National Registry
NCT03325855
Recruiting
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Fecal Microbiota Transplantation, Clostridium Difficile Infection, Gut Microbiome
Register for Updates
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
NCT03141021
Recruiting
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Malignant Peripheral Nerve Sheath Tumors
Register for Updates